Myasthenia Gravis Plasma
Myasthenia Gravis Plasma - Cryopreserved human plasma from clinically confirmed myasthenia gravis donors. Ideal for profiling AChR and MuSK autoantibodies, complement proteins, and inflammatory cytokines, with AChR-positive, MuSK-positive, and seronegative donors available.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 75192 | Myasthenia Gravis | 1.0 ML | Caucasian | 65 | Male | United States |
VYVGART IV infusion, scheduled every week CellCept 1500mg BID Prednisone 5mg QD Ibuprofen 400 mg BID PRN omeprazole 20mg QD
|
11 | $495.00 | |
| 74321 | Myasthenia Gravis | 1.0 ML | African American | 54 | Female | United States |
Prednisone/10mg/QD Munjaro 2.5 mg QW Rosuvastatin 5mg QD Olmesartan medoxomil 5 mg QD Low estrogen
|
16 | $495.00 | |
| 73627 | Myasthenia Gravis | 1.0 ML | Caucasian | 33 | Female | United States |
(IV infusion treatments- IVIG & Soliris: get at Ivx heath) **IV bard power port needle 3/4ths** *Soliris IV 1200 mg: 1 day every other week (started 2020) Vvygart Infusion start 2026, weekly on Mondays x4 revaluating *Amitriptyline 10 mg: 4 at night *Prednisone 10 mg: 5 in morning *Emgality: once a month on the 9th. (Started 2023) *Calcium 600 mg plus D3 20 mcg: 1 in morning *Folic acid: 1mg tablets *B12 1000 mcg: 1 in morning --As Needed Meds-- *Ubrelvy mg: as needed -Continuous Meds- *Testosterone CYP 120 mg/ .6 ml subcutaneous: once every Wednesday *Lamictal 200 mg ER: 1 in morning, 1 at night *Ritalin 20 mg: 1 pill morning, 1 pill noon *buspar 10 mg: 1 pill morning, 1 pill noon, 1 pill at night *Lexapro 20 mg: 1 in morning *Seroquel 100 mg er: 3 at night Eliquis -As Needed Meds- *Lorazepam 1 mg: as needed *Hydroxyzine: as needed Amlodipine tab 10mg: 1 in morning *Topamax 50 mg: 1 in morning, 1 at night *Ropinirole HCL 3 mg: 1 at night *BIPAP: Pressure 18 over 13 *Famotidine 20 mg: 1 in morning, 1 at night --As Needed Meds-- *Ondansetron ODT 4 mg: as needed Eye gel lubricant drops- 3 times a day *Retin-A (tretinoin) cream 0.1%: at night every few days as tolerated where acne is *Clindamycin Phosphate Topical solution USP, 1%: Put on back, chest and shoulders once in morning, once at night *Finacea (azealic acid) *Ventolin HFA 90 mcg per actuation: as needed *Trimodal 50mg: as needed *Triamcinolone Acetonide ointment USP, 0.1%: as needed
|
17 | $495.00 | |
| 73889 | Myasthenia Gravis | 1.0 ML | Caucasian | 65 | Female | United States |
Methotrexate Prednisone 2 rounds of Rystiggo -MG Calcium Folic Acid Lisinopril
|
8 | $495.00 | |
| 73547 | Myasthenia Gravis | 1.0 ML | Caucasian | 54 | Female | United States |
Zilbrysq Rosuvastatin 40mg QD Buspirone 5Mg 3 times daily
|
13 | $495.00 | |
| 73388 | Myasthenia Gravis | 1.0 ML | Caucasian | 67 | Female | United States |
Mestinon/60mg/4 times daily Prednisone tapering dose IVIG one dose 10/2025 (yearly) Zetia for cholesterol
|
11 | $495.00 | |
| 73743 | Myasthenia Gravis | 1.0 ML | Caucasian | 70 | Female | United States |
Prednisone/10mg/QD Duloxetine Zolpidem/QPM Folic Acid Eliquis 5 mg BID Sulfasalazine Lamitrogine Metoprolol Ozempic History of: Mestinon/60mg/TID
|
16 | $495.00 | |
| 73394 | Myasthenia Gravis | 1.0 ML | Caucasian | 39 | Female | United States |
Rituximab Mestinon 120 mg TID Prednisone 20 mg QD Prozac 50mg QD Gabapentin 300mg TID Seroquel 100mg QD
|
16 | $495.00 | |
| 73628 | Myasthenia Gravis | 1.0 ML | Caucasian | 59 | Male | United States |
Atorvastatin 40 mg for cholesterol QD Bilt-XR 240 mg blood pressure medication QD Omeprazole 20 mg QD Lisinopril 10 mg QD Baby aspirin 81 mg QD Allegra PRN
|
11 | $495.00 | |
| 73320 | Myasthenia Gravis | 1.0 ML | Caucasian | 47 | Female | United States |
Hizentra Immune Globulin Subcutaneous Junel 1.5/30 (birth control) low dose naltrexone 4.5mg QD T4 levothyroxine 220mcg QD T3 Liothyronine 48mcg QD History of IVIG
|
13 | $495.00 |
Myasthenia Gravis Plasma for Autoimmune Neuromuscular Junction Research
Myasthenia Gravis Plasma is collected from IRB-consented donors clinically diagnosed with myasthenia gravis (MG) and processed within one day of collection to preserve autoantibodies, complement proteins, cytokines, and other labile analytes. MG is an antibody-mediated autoimmune disease of the neuromuscular junction: pathogenic IgG autoantibodies against the postsynaptic acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) impair neuromuscular transmission, producing fatigable weakness.
Disease Biology and Why Plasma
- AChR autoantibodies are present in the majority of generalised MG donors and act through complement-mediated damage to the postsynaptic membrane, receptor cross-linking and internalisation, and direct blockade of acetylcholine binding.
- MuSK autoantibodies define a distinct, predominantly IgG4 subgroup that disrupts agrin-LRP4-MuSK signalling and postsynaptic AChR clustering rather than acting through complement.
- Complement activation is central to AChR-positive disease and is the target of approved therapeutics; plasma preserves complement components and activation products for pathway analysis.
- Seronegative and low-affinity antibody donors support cell-based assay development and discovery of additional autoantigens such as LRP4 and agrin.
- IgG-directed therapeutics: FcRn antagonists and complement inhibitors are assessed through circulating total IgG and antibody titre, both plasma-appropriate readouts.
- Plasma is acellular and is the correct matrix for autoantibody titration, complement profiling, cytokine multiplexing, proteomics, and metabolomics. For cellular assays, see the PBMC and leukopak products below.
Donor Stratification Available
- Serostatus: AChR-positive, MuSK-positive, or seronegative
- Clinical subtype: ocular versus generalised MG
- Thymic pathology: thymoma-associated, thymic hyperplasia, or post-thymectomy
- Age at onset: early-onset versus late-onset disease
- Treatment status: acetylcholinesterase inhibitors, corticosteroids, non-steroidal immunosuppressants, rituximab, complement inhibitors, FcRn antagonists, IVIg or plasma exchange, or treatment-naive
- Disease activity: stable, exacerbation, or history of myasthenic crisis
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed MG donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified MG diagnosis
- Serostatus (AChR, MuSK) where available
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Additional myasthenia gravis-specific metadata available
Applications
- AChR and MuSK autoantibody detection, titration, and isotype analysis
- Radioimmunoassay, ELISA, and cell-based assay development and validation
- Complement activation and complement inhibitor pharmacodynamic research
- FcRn antagonist and IgG-lowering therapeutic research
- Novel autoantigen discovery in seronegative donors
- Cytokine and inflammation profiling
- Proteomic and metabolomic biomarker discovery
- Treatment response and disease activity biomarker studies
Other Myasthenia Gravis Specimen Types
MG donor material is also available as Myasthenia Gravis Serum, Myasthenia Gravis PBMC, Myasthenia Gravis Whole Blood, Myasthenia Gravis Leukopak, and Myasthenia Gravis Bulk Plasma for larger-volume requirements. Subtype-specific plasma is available as AChR+ Myasthenia Gravis Plasma, Ocular Myasthenia Gravis Plasma, Generalized Myasthenia Gravis Plasma, and Seronegative Myasthenia Gravis Plasma.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Myasthenia gravis plasma is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. For the full specimen range, see our human plasma collection.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.